Peptides for Anxiety: Selank & the Evidence

Selank is the most-studied peptide for anxiety. It is a synthetic heptapeptide derived from the immune peptide tuftsin, researched mainly in Russia as an anxiolytic that does not sedate or cause dependence. Human trials are small and largely non-English; it is not FDA-approved. This guide reviews the mechanism, evidence, dosing context, and 2026 legal status.

Selank for anxiety at a glance

• Class: synthetic heptapeptide (tuftsin analog; research peptide)
• Proposed mechanism: allosteric modulation of GABAergic signaling; enkephalin and BDNF effects
• Commonly cited research dose: 250–500 mcg (nasal), often divided through the day
• Route most studied: intranasal
• Best-studied for: generalized anxiety and asthenic (low-energy) states — small human trials plus animal models
• Human evidence level: limited; small comparative trials, mostly Russian-language
• FDA status (June 2026): not approved; was not among the 12 peptides removed from the 503A "Category 2" list in April 2026, and is not on the July 23–24, 2026 PCAC agenda. Its compounding status remains unsettled [VERIFY: Selank's current 503A category and any scheduled FDA review — confirm against the live FDA tracker]

What does the research say about peptides for anxiety?

Most peptides marketed for anxiety have little or no direct human evidence. The clear exception in the published literature is Selank, which has been studied specifically as an anxiolytic in both animal models and small human trials. For that reason, Selank is the focus of this guide — when people search "peptides for anxiety," it is the molecule the evidence actually points to.

That said, the evidence base is modest. The strongest human work consists of small comparative trials conducted in Russia, where Selank is a registered medication, and much of it is published in Russian-language psychiatry journals with limited English data. Selank is not FDA-approved in the United States and has not completed the large, placebo-controlled trials that Western regulators typically require. Treat what follows as a summary of early, preliminary science — not a recommendation.

What is Selank?

Selank is a synthetic heptapeptide (seven amino acids) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is a stabilized analog of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin G molecule with immune-modulating activity. Selank adds amino acids to the tuftsin sequence to slow its breakdown in the body and extend its activity.

Because it is a peptide, Selank is poorly absorbed if swallowed, so research has focused on the intranasal route. In Russia it is registered as a prescription anxiolytic; in the United States it has no FDA-approved use and is handled as a research compound. For a deeper structural and pharmacology breakdown, see our Selank complete guide, and for the cognition-focused sibling peptide, our Semax complete guide.

How does Selank work for anxiety?

Selank's proposed anti-anxiety mechanism centers on the GABA system — the same broad pathway targeted by benzodiazepines, but reached indirectly. In a gene-expression study, Selank (300 mcg/kg) altered the expression of dozens of genes tied to GABAergic neurotransmission in rat brain within one hour, with changes the authors interpreted as allosteric modulation of the GABAergic system rather than direct receptor binding (Volkova et al., 2016, Frontiers in Pharmacology). Animal work also suggests Selank can enhance the activity of diazepam: in stressed rats, combining the two produced greater anxiety reduction than either alone, consistent with Selank increasing GABA-A receptor sensitivity (Kasian et al., 2017, Behavioural Neurology).

Beyond GABA, researchers have described two additional proposed pathways. Selank appears to slow the breakdown of enkephalins — endogenous peptides involved in stress and mood regulation — and, in human trials, increased serum enkephalin half-life correlated with anxiety reduction (Zozulia et al., 2008, Zh Nevrol Psikhiatr). It has also been reported to influence BDNF (brain-derived neurotrophic factor) and serotonin turnover in animal studies. These are mechanistic findings in animal models and small human cohorts, not proof of clinical benefit. Consult your healthcare provider before drawing conclusions about how Selank might affect your physiology.

What is the evidence that Selank reduces anxiety?

The human evidence is limited but specific. The most-cited trial enrolled 62 patients with generalized anxiety disorder (GAD) and neurasthenia, comparing Selank against the benzodiazepine medazepam. The authors reported that Selank produced anxiolytic effects characterized as comparable to medazepam on the Hamilton, Zung, and Clinical Global Impression scales, with additional anti-asthenic (anti-fatigue) effects and changes in serum enkephalin activity that tracked with symptom improvement (Zozulia et al., 2008, Zh Nevrol Psikhiatr, PMID 18454096). A separate human study in patients with anxiety-asthenic disorders reported immunomodulatory effects — shifts in the Th1/Th2 cytokine balance — alongside its anxiolytic profile (Uchakina et al., 2008, Zh Nevrol Psikhiatr, PMID 18577961).

Two important caveats apply. First, these trials are small and were conducted by the molecule's developers in the country where it is marketed; the English-language abstracts often do not report effect sizes, p-values, or responder rates, so the "comparable to a benzodiazepine" framing is largely qualitative. Second, there are no large, independent, placebo-controlled Western trials. The animal literature is more developed and consistently shows anxiolytic-type behavior in stress models (Kasian et al., 2017), but animal results do not reliably predict human outcomes. In short: research in animal models and small human trials suggests Selank may support reduced anxiety, but the evidence does not establish it as a treatment.

What dose of Selank is used in research?

Research and compounded protocols most commonly cite 250–500 mcg of intranasal Selank per day, sometimes divided into smaller doses across the day; some clinical protocols have used higher daily totals (one published human study used roughly 2,700 mcg/day intranasally). In animal studies, a frequently used dose is 300 mcg/kg, which does not translate directly to a human dose. There is no FDA-established dose, no standardized commercial formulation in the U.S., and wide variation between sources.

Because Selank is not FDA-approved, any product sold for human use in the U.S. exists outside the standard approval framework, and purity, concentration, and labeling can vary substantially between vendors. Dosing should never be self-directed from an article. Consult your healthcare provider before starting any peptide protocol, and discuss whether evidence-based anxiety treatments are a better fit for your situation.

Is Selank safe? What are the side effects?

Reported side effects in the available literature are generally described as mild — the human trials emphasized the absence of the sedation, cognitive dulling, tolerance, and dependence associated with benzodiazepines (Zozulia et al., 2008). Some users and protocols report transient nasal irritation, fatigue, or mild changes in mood or blood pressure, but these are not well quantified in controlled data.

The more important safety point is what is not known. There is no long-term human safety data, no large safety database, and limited information on interactions with prescription medications — including the benzodiazepines and antidepressants commonly used for anxiety, where additive effects are plausible given the shared GABA and serotonin pathways. People with anxiety disorders frequently have co-occurring conditions and take other medications, which raises the stakes for unsupervised use. Anxiety can also be a symptom of medical conditions that require evaluation. Because anxiety is a diagnosable health condition, do not substitute an unapproved peptide for professional care. Consult your healthcare provider before starting any peptide protocol, especially if you take other psychiatric or cardiovascular medications.

Is Selank legal? What is its FDA status in 2026?

Selank is not FDA-approved for any use in the United States. Its regulatory status was the subject of broader 2026 activity around peptide compounding, but Selank itself sits apart from the peptides that moved this spring. In April 2026, the FDA removed 12 peptides from the 503A "Category 2" bulk-substances designation — the category that had effectively blocked their use in pharmacy compounding (FDA 503A bulk drug substances framework, 2026). That list was BPC-157, TB-500, KPV, MOTS-c, DSIP/emideltide, Semax, Epitalon, LL-37, Dihexa, GHK-Cu, PEG-MGF, and Melanotan II — Selank was not among them. And, importantly, removal from Category 2 does not by itself make a substance legal to compound: it does not place a peptide on the 503A bulks list or into the enforcement-discretion "Category 1."

The next step for those substances is the Pharmacy Compounding Advisory Committee (PCAC), which is scheduled to meet July 23–24, 2026 to review seven peptides for possible addition to the 503A list — BPC-157, KPV, TB-500, and MOTS-c on Day 1, and DSIP/emideltide, Semax, and Epitalon on Day 2 (FDA Advisory Committee Calendar, 2026). Selank is not on that July agenda. Its own status is unsettled: reporting in 2026 has been mixed on whether and when Selank will be reclassified or formally reviewed [VERIFY: Selank's current 503A category and any scheduled PCAC date — confirm against the FDA Category 2 list and Advisory Committee Calendar before publication]. PCAC recommendations are non-binding, and even a favorable vote would require formal notice-and-comment rulemaking that can take more than a year. For the live picture across all peptides, see our 2026 FDA peptide status tracker. Legal status varies by jurisdiction; consult a lawyer for binding advice.

Selank and anxiety care in NYC

If you are exploring peptides for anxiety in New York, the responsible path runs through a licensed clinician — not a direct purchase. A provider can evaluate whether your symptoms warrant first-line, evidence-based anxiety care, screen for interactions with any medications you take, and explain the current compounding and legal constraints. You can browse vetted practitioners on our Peptides.NYC practitioner directory. Peptides.NYC does not sell peptides and does not provide medical care; we provide education to help you have a more informed conversation with a professional.

Frequently asked questions

Q: What are the best peptides for anxiety? A: Selank is the peptide with the most anxiety-specific research, including small human trials and animal studies suggesting it may support reduced anxiety through GABAergic and enkephalin-related pathways. Semax, a related peptide, is studied more for cognition and mood than anxiety specifically. None are FDA-approved for anxiety, the human evidence is limited, and "best" is not established. Evidence-based, professionally guided treatments remain the standard of care. Consult your healthcare provider before considering any peptide for anxiety.

Q: Is Selank as effective as Xanax or other benzodiazepines? A: A small 2008 Russian trial reported that Selank's anxiolytic effect was characterized as comparable to the benzodiazepine medazepam on standard rating scales, without the sedation or dependence benzodiazepines can cause (Zozulia et al., 2008). However, the trial was small, conducted by the developers, and did not report detailed effect sizes, and there are no large independent trials. This is not evidence that Selank can replace a prescribed medication. Never stop or change a prescription without your provider.

Q: How is Selank taken for anxiety? A: In research, Selank is most often administered intranasally, with commonly cited doses around 250–500 mcg per day, sometimes divided; some clinical protocols used higher daily totals. There is no FDA-approved dose or standardized U.S. formulation, and purity varies by source. Because Selank is unapproved and dosing is not standardized, any use should be supervised. Consult your healthcare provider before starting any peptide protocol.

Q: Does Selank cause withdrawal or dependence? A: A frequently cited advantage of Selank in the published human trials is the reported absence of tolerance, dependence, and withdrawal seen with benzodiazepines (Zozulia et al., 2008). However, long-term human safety data are lacking, so the absence of dependence risk over months or years is not firmly established. Do not assume any compound is risk-free. Discuss safety with your healthcare provider.

Q: Is Selank legal in the US in 2026? A: Selank is not FDA-approved. When the FDA removed 12 peptides from the 503A "Category 2" list in April 2026, Selank was not one of them, and it is not on the July 23–24, 2026 PCAC agenda (which covers BPC-157, KPV, TB-500, MOTS-c, DSIP/emideltide, Semax, and Epitalon). Selank's own compounding status remains unsettled, and any path to legal compounding would require further FDA action [VERIFY: Selank's current 503A category — confirm against the FDA Category 2 list before publication]. Legal status varies by jurisdiction; consult a lawyer for binding advice.

Q: How long does Selank take to work for anxiety? A: In the human trials, anxiolytic effects were measured over treatment courses of about two weeks, and some users report acute effects within hours of a dose. Animal studies also show rapid behavioral effects. Timelines and individual response vary, and the data are limited. Set expectations with a healthcare provider rather than from anecdotal reports.

Q: Can I use Selank with my anxiety medication? A: This is not well studied. Selank acts on GABA and serotonin-related pathways that overlap with benzodiazepines and antidepressants, so additive or unpredictable effects are plausible. Combining unapproved peptides with prescription psychiatric medication should never be done without medical supervision. Consult your healthcare provider before combining anything with your current treatment.

References

1. Zozulia AA, Neznamov GG, Siuniakov TS, et al. [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48. PMID: 18454096. https://pubmed.ncbi.nlm.nih.gov/18454096/
2. Uchakina ON, Uchakin PN, Miasoedov NF, et al. [Immunomodulatory effects of selank in patients with anxiety-asthenic disorders]. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(5):71-75. PMID: 18577961. https://pubmed.ncbi.nlm.nih.gov/18577961/
3. Kasian A, Kolomin T, Andreeva L, et al. Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Behav Neurol. 2017;2017:5091027. PMID: 28280289. DOI: 10.1155/2017/5091027. https://pmc.ncbi.nlm.nih.gov/articles/PMC5322660/
4. Volkova A, Shadrina M, Kolomin T, et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Front Pharmacol. 2016;7:31. PMID: 26924987. DOI: 10.3389/fphar.2016.00031. https://pmc.ncbi.nlm.nih.gov/articles/PMC4757671/
5. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. FDA Advisory Committee Calendar, 2026. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
6. U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (Category 2 removals, April 2026). https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding-under-section-503a-federal-food-drug-and-cosmetic-act